- AmbioPharm aims for a holistic reduction of the carbon footprint by factoring in the complete manufacturing and supply chain impact in addition to greener chemistry initiatives.
NORTH AUGUSTA, S.C.–(BUSINESS WIRE)–#cGMP—AmbioPharm, a worldwide leader in peptide API CDMO services, to host a workshop on sustainable peptide manufacturing at Biologics 2023 taking place in London, UK on March 29, 2023. The workshop, entitled “Holistic Approaches to Sustainable Peptide Manufacturing,” will comprise of industry presentations and a roundtable discussion with AmbioPharm and industry leaders from Novo Nordisk and Astra Zeneca.
The peptide manufacturing industry, like others, is pushing strongly towards sustainable manufacturing practices. Making peptide manufacturing more sustainable includes several aspects of the process, from supply chain, to chemistry, and beyond. “Developing sustainable and greener production of peptides is not only a mandate for our company, but a commitment to our clients as well as to the future of our planet and its health,” said Michael Pennington, Ph.D., CSO of AmbioPharm.
The workshop aims to look into the various ways we can holistically improve sustainability in peptide manufacturing. This includes important “green” approaches to chemistry such as coupling efficiencies and solvent reduction, recycling and replacement. Sustainable manufacturing is more than the chemistry, and also includes outside elements such as the carbon footprint of energy use in the process as well as in the supply chain. AmbioPharm aims for a holistic reduction of the carbon footprint by factoring in the complete manufacturing and supply chain impact in addition to greener chemistry initiatives.
About AmbioPharm:
AmbioPharm is a leading and innovation-driven company specializing in the development and manufacture of peptides and peptide-related products. With a comprehensive range of services and scales, AmbioPharm produces custom products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. Headquartered in the United States of America and with campuses in both the USA and Asia, AmbioPharm operates internationally with extensive experience and expertise. Further information is available at: https://www.ambiopharm.com
Contacts
Mark DaFonseca, EVP, Sales & Global Business Development
mark.dafonseca@ambiopharm.com